Immune and Immune-Integrated Organoids as NextGeneration Platforms for Disease Modeling

Abstract

Organoids are three-dimensional structures that closely resemble the architecture and functions of human organs, offering key advantages over traditional models by better replicating tissue complexity and cellular interactions. These systems have become invaluable tools for disease modeling, drug screening, and regenerative medicine applications. Despite this progress, their lack of immune components limits their usefulness in diseases where immune cells are central drivers of pathology and therapy. The absence of an immune system within organoids limits their physiological relevance, particularly for cancer, inflammation, and autoimmunity research. Immune cell-containing organoids provide a comprehensive platform for immunotherapy, host–pathogen interactions, regeneration, and immune disorders. This review first highlights the transformative potential of immune cell-containing organoids across cancer, infection, inflammation, autoimmunity, regeneration, and the modeling of primary lymphoid organs. It then examines current strategies for integrating immune cells into organoids, the variety of immune cell sources employed, and the challenges in maintaining immune cell function. Finally, the role of bioengineering, biobanking, and artificial intelligence in overcoming existing limitations and enhancing immune system modeling is discussed. Overall, this study positions immune cell-containing organoids as powerful platforms for translational research and precision medicine.

Keywords

cancer / immune cell / inflammation / organoid / pluripotent stem cell / regenerative medicine

References

[1] N. Maherali, R. Sridharan, W. Xie, et al., “Directly Reprogrammed Fibroblasts Show Global Epigenetic Remodeling and Widespread Tissue Contribution,” Cell Stem Cell 1, no. 1 (2007): 55–70.

[2] K. Takahashi, K. Tanabe, M. Ohnuki, et al., “Induction of Pluripotent Stem Cells From Adult Human Fibroblasts by Defined Factors,” Cell 131, no. 5 (2007): 861–872.

[3] M. Wernig, A. Meissner, R. Foreman, et al., “In Vitro Reprogramming of Fibroblasts Into a Pluripotent ES-Cell-Like state,” Nature 448, no. 7151 (2007): 318–324.

[4] R. Haberberger, C. Barry, and D. Matusica, “Immortalized Dorsal Root Ganglion Neuron Cell Lines,” Frontiers in Cellular Neuroscience 14 (2020): 184.

[5] P. Hunter, “The Paradox of Model Organisms: The Use of Model Organisms in Research Will Continue Despite Their Shortcomings,” EMBO Reports 9, no. 8 (2008): 717–720.

[6] A. Love and Y. Yoshida, “Reflections on Model Organisms in Evolutionary Developmental Biology,” Results and Problems in Cell Differentiation 68 (2019): 3–20.

[7] E. Ramboer, T. Vanhaecke, V. Rogiers, and M. Vinken, “Immortalized Human Hepatic Cell Lines for In Vitro Testing and Research Purposes,” Methods in Molecular Biology 1250 (2015): 53–76.

[8] R. Hinton and K. Yutzey, “Heart Valve Structure and Function in Development and Disease,” Annual Review of Physiology 73 (2011): 29–46.

[9] T. Mammoto and D. Ingber, “Mechanical Control of Tissue and Organ Development,” Development (Cambridge, England) 137, no. 9 (2010): 1407–1420.

[10] M. Bissell, “The Differentiated State of Normal and Malignant Cells or How to Define a “Normal” Cell in Culture,” International Review of Cytology 70 (1981): 27–100.

[11] T. Sato, R. G. Vries, H. J. Snippert, et al., “Single Lgr5 Stem Cells Build Crypt-villus Structures In Vitro Without a Mesenchymal Niche,” Nature 459, no. 7244 (2009): 262–265.

[12] M. A. Lancaster, M. Renner, C. Martin, et al., “Cerebral Organoids Model Human Brain Development and Microcephaly,” Nature 501, no. 7467 (2013): 373–379.

[13] J. Lee, C. C. Rabbani, H. Gao, et al., “Hair-Bearing Human Skin Generated Entirely From Pluripotent Stem Cells,” Nature 582, no. 7812 (2020): 399–404.

[14] G. Rossi, A. Manfrin, and M. Lutolf, “Progress and Potential in Organoid Research,” Nature Reviews Genetics 19, no. 11 (2018): 671–687.

[15] H. Clevers, “Modeling Development and Disease With Organoids,” Cell 165, no. 7 (2016): 1586–1597.

[16] C. Corrò, L. Novellasdemunt, and V. Li, “A Brief History of Organoids,” American Journal of Physiology Cell Physiology 319, no. 1 (2020): C151–C165.

[17] S. Min, S. Kim, and S. Cho, “Gastrointestinal Tract Modeling Using Organoids Engineered With Cellular and Microbiota Niches,” Experimental & Molecular Medicine 52, no. 2 (2020): 227–237.

[18] J. Kong, S. Wen, W. Cao, et al., “Lung Organoids, Useful Tools for Investigating Epithelial Repair After Lung Injury,” Stem Cell Research & Therapy 12 (2021): 1–13.

[19] R. Romero-Guevara, A. Ioannides, and C. Xinaris, “Kidney Organoids as Disease Models: Strengths, Weaknesses and Perspectives,” Frontiers in Physiology 11 (2020): 563981.

[20] Y. Lewis-Israeli, A. Wasserman, and A. Aguirre, “Heart Organoids and Engineered Heart Tissues: Novel Tools for Modeling Human Cardiac Biology and Disease,” Biomolecules 11, no. 9 (2021): 1277.

[21] S. P. Harrison, S. F. Baumgarten, R. Verma, O. Lunov, A. Dejneka, and G. J. Sullivan, “Liver Organoids: Recent Developments, Limitations and Potential,” Frontiers in Medicine 8 (2021): 574047.

[22] A. Shafiee, J. Sun, I. A. Ahmed, et al., “Development of Physiologically Relevant Skin Organoids From Human Induced Pluripotent Stem Cells,” Small 20, no. 16 (2024): e2304879.

[23] R. A. Wimmer, A. Leopoldi, M. Aichinger, et al., “Human Blood Vessel Organoids as a Model of Diabetic Vasculopathy,” Nature 565, no. 7740 (2019): 505–510.

[24] Q. Yao, S. Cheng, Q. Pan, et al., “Organoids: Development and Applications in Disease Models, Drug Discovery, Precision Medicine, and Regenerative Medicine,” MedComm 5, no. 10 (2024): e735.

[25] A. Shpichka, P. Bikmulina, M. Peshkova, et al., “Organoids in Modelling Infectious Diseases,” Drug Discovery Today 27, no. 1 (2022): 223–233.

[26] J. Kim, B. Koo, and J. Knoblich, “Human Organoids: Model Systems for Human Biology and Medicine,” Nature Reviews Molecular Cell Biology 21, no. 10 (2020): 571–584.

[27] L. Wagar, “Human Immune Organoids: A Tool to Study Vaccine Responses,” Nature Reviews Immunology 23, no. 11 (2023): 699–699.

[28] A. Hammerhøj, D. Chakravarti, T. Sato, K. B. Jensen, and O. H. Nielsen, “Organoids as Regenerative Medicine for Inflammatory Bowel Disease,” iScience 27, no. 6 (2024): 6110118.

[29] G. Noel, N. W. Baetz, J. F. Staab, et al., “A Primary Human Macrophage-Enteroid Co-Culture Model to Investigate Mucosal Gut Physiology and Host-Pathogen Interactions,” Scientific Reports 7, no. 1 (2017): 45270.

[30] H. Heo and S. Hong, “Generation of Macrophage Containing Alveolar Organoids Derived From Human Pluripotent Stem Cells for Pulmonary Fibrosis Modeling and Drug Efficacy Testing,” Cell & Bioscience 11, no. 1 (2021): 216.

[31] J. Kim, B. Koo, and J. Knoblich, “Human Organoids: Model Systems for Human Biology and Medicine,” Nature Reviews Molecular Cell Biology 21, no. 10 (2020): 571–584.

[32] C. Jensen and Y. Teng, “Is It Time to Start Transitioning from 2D to 3D Cell Culture?,” Frontiers in Molecular Biosciences 7 (2020): 33.

[33] M. Kapałczyńska, T. Kolenda, W. Przybyła, et al., “2D and 3D Cell Cultures—A Comparison of Different Types of Cancer Cell Cultures,” Archives of Medical Science 14, no. 4 (2018): 910–919.

[34] J. Drost and H. Clevers, “Organoids in Cancer Research,” Nature Reviews Cancer 18, no. 7 (2018): 407–418.

[35] L. Magré, M. M. A. Verstegen, S. Buschow, L. J. W. van der Laan, M. Peppelenbosch, and J. Desai, “Emerging Organoid-Immune Co-Culture Models for Cancer Research: From Oncoimmunology to Personalized Immunotherapies,” Journal for ImmunoTherapy of Cancer 11, no. 5 (2023): e006290.

[36] M. van de Wetering, H. E. Francies, J. M. Francis, et al., “Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients,” Cell 161, no. 4 (2015): 933–945.

[37] J. T. Neal, X. Li, J. Zhu, et al., “Organoid Modeling of the Tumor Immune Microenvironment,” Cell 175, no. 7 (2018): 1972–1988.e16.

[38] J. Drost, R. van Boxtel, F. Blokzijl, et al., “Use of CRISPR-Modified Human Stem Cell Organoids to Study the Origin of Mutational Signatures in Cancer,” Science 358, no. 6360 (2017): 234–238.

[39] B. E. Michels, M. H. Mosa, B. I. Streibl, et al., “Pooled In Vitro and In Vivo CRISPR-Cas9 Screening Identifies Tumor Suppressors in Human Colon Organoids,” Cell Stem Cell 26, no. 5 (2020): 782–792.e7.

[40] S. A. Sloan, J. Andersen, A. M. Pașca, F. Birey, and S. P. Pașca, “Generation and Assembly of Human Brain Region-Specific Three-Dimensional Cultures,” Nature Protocols 13, no. 9 (2018): 2062–2085.

[41] R. Levy and S. Paşca, “What Have Organoids and Assembloids Taught Us about the Pathophysiology of Neuropsychiatric Disorders?,” Biological Psychiatry 93, no. 7 (2023): 632–641.

[42] F. Birey, J. Andersen, C. D. Makinson, et al., “Assembly of Functionally Integrated Human Forebrain Spheroids,” Nature 545, no. 7652 (2017): 54–59.

[43] S. Paşca, “Assembling Human Brain Organoids,” Science 363, no. 6423 (2019): 126–127.

[44] X. Qian, H. Nguyen, M. Song, et al., “Brain-Region-Specific Organoids Using Mini-Bioreactors for Modeling ZIKV Exposure,” Cell 165, no. 5 (2016): 1238–1254.

[45] S. Grebenyuk and A. Ranga, “Engineering Organoid Vascularization,” Frontiers in Bioengineering and Biotechnology 7 (2019): 39.

[46] A. Fatehullah, S. Tan, and N. Barker, “Organoids as an In Vitro Model of Human Development and Disease,” Nature Cell Biology 18, no. 3 (2016): 246–254.

[47] M. Lancaster and J. Knoblich, “Organogenesis in a Dish: Modeling Development and Disease Using Organoid Technologies,” Science 345, no. 6194 (2014): 1247125.

[48] X. Qian, H. Song, and G. Ming, “Brain Organoids: Advances, Applications and Challenges,” Development (Cambridge, England) 146, no. 8 (2019): dev166074.

[49] Y. Huang, Z. Huang, Z. Tang, et al., “Research Progress, Challenges, and Breakthroughs of Organoids as Disease Models,” Frontiers in Cell and Developmental Biology 9 (2021): 740574.

[50] Y. Bar-Ephraim, K. Kretzschmar, and H. Clevers, “Organoids in Immunological Research,” Nature Reviews Immunology 20, no. 5 (2020): 279–293.

[51] E. Daniel and O. Cleaver, “Vascularizing Organogenesis: Lessons From Developmental Biology and Implications for Regenerative Medicine,” Current Topics in Developmental Biology 132 (2019): 177–220.

[52] T. Takebe and J. Wells, “Organoids by Design,” Science 364, no. 6444 (2019): 956–959.

[53] J. Zhu, J. Zhou, B. Feng, et al., “MSCs Alleviate LPS-Induced Acute Lung Injury by Inhibiting the Proinflammatory Function of Macrophages in Mouse Lung Organoid-Macrophage Model,” Cellular and Molecular Life Sciences 81, no. 1 (2024): 124.

[54] K. Yuki, N. Cheng, M. Nakano, and C. J. Kuo, “Organoid Models of Tumor Immunology,” Trends in Immunology 41, no. 8 (2020): 652–664.

[55] B. Lin, L. Du, H. Li, X. Zhu, L. Cui, and X. Li, “Tumor-Infiltrating Lymphocytes: Warriors Fight Against Tumors Powerfully,” Biomedicine & Pharmacotherapy 132 (2020): 110873.

[56] A. Mantovani, F. Marchesi, A. Malesci, L. Laghi, and P. Allavena, “Tumour-Associated Macrophages as Treatment Targets in Oncology,” Nature Reviews Clinical Oncology 14, no. 7 (2017): 399–416.

[57] T. H. S. Ng, G. J. Britton, E. V. Hill, J. Verhagen, B. R. Burton, and D. C. Wraith, “Regulation of Adaptive Immunity; the Role of Interleukin-10,” Frontiers in Immunology 4 (2013): 129.

[58] R. H. McIntire, P. J. Morales, M. G. Petroff, M. Colonna, and J. S. Hunt, “Recombinant HLA-G5 and-G6 Drive U937 Myelomonocytic Cell Production of TGF-β1,” Journal of Leukocyte Biology 76, no. 6 (2004): 1220–1228.

[59] Y. P. Rubtsov, J. P. Rasmussen, E. Y. Chi, et al., “Regulatory T Cell-Derived Interleukin-10 Limits Inflammation at Environmental Interfaces,” Immunity 28, no. 4 (2008): 546–558.

[60] S. Liu, V. Galat, Y. Galat, Y. K. A. Lee, D. Wainwright, and J. Wu, “NK Cell-Based Cancer Immunotherapy: From Basic Biology to Clinical Development,” Journal of Hematology & Oncology 14 (2021): 1–17.

[61] O. Melaiu, M. Chierici, V. Lucarini, et al., “Cellular and Gene Signatures of Tumor-Infiltrating Dendritic Cells and Natural-Killer Cells Predict Prognosis of Neuroblastoma,” Nature Communications 11, no. 1 (2020): 5992.

[62] B. Farhood, M. Najafi, and K. Mortezaee, “CD8+ Cytotoxic T Lymphocytes in Cancer Immunotherapy: A Review,” Journal of Cellular Physiology 234, no. 6 (2019): 8509–8521.

[63] F. Veglia, M. Perego, and D. Gabrilovich, “Myeloid-Derived Suppressor Cells Coming of Age,” Nature Immunology 19, no. 2 (2018): 108–119.

[64] M. Duffy and J. Crown, “A Personalized Approach to Cancer Treatment: How Biomarkers Can Help,” Clinical Chemistry 54, no. 11 (2008): 1770–1779.

[65] C. Röcken, “Molecular Classification of Gastric Cancer,” Expert Review of Molecular Diagnostics 17, no. 3 (2017): 293–301.

[66] J. Rodriguez-Canales, E. Parra-Cuentas, and I. I. Wistuba, “Diagnosis and Molecular Classification of Lung Cancer,” Cancer Treatment and Research 170 (2016): 25–46.

[67] J. Tsang and G. Tse, “Molecular Classification of Breast Cancer,” Advances in Anatomic Pathology 27, no. 1 (2020): 27–35.

[68] M. Bleijs, M. van de Wetering, H. Clevers, and J. Drost, “Xenograft and Organoid Model Systems in Cancer Research,” EMBO Journal 38, no. 15 (2019): e101654.

[69] N. de Souza, “Organoids,” Nature Methods 15, no. 1 (2018): 23–23.

[70] M. Li and J. Izpisua Belmonte, “Organoids—Preclinical Models of Human Disease,” New England Journal of Medicine 380, no. 6 (2019): 569–579.

[71] H. Jin, Q. Yang, J. Yang, et al., “Exploring Tumor Organoids for Cancer Treatment,” APL Materials 12, no. 6 (2024): 060602.

[72] Y. Lo, K. Karlsson, and C. Kuo, “Applications of Organoids for Cancer Biology and Precision Medicine,” Nat Cancer 1, no. 8 (2020): 761–773.

[73] T. Sato, D. E. Stange, M. Ferrante, et al., “Long-Term Expansion of Epithelial Organoids From human Colon, Adenoma, Adenocarcinoma, and Barrett's Epithelium,” Gastroenterology 141, no. 5 (2011): 1762–1772.

[74] F. Pampaloni, E. Reynaud, and E. Stelzer, “The Third Dimension Bridges the Gap Between Cell Culture and Live Tissue,” Nature Reviews Molecular Cell Biology 8, no. 10 (2007): 839–845.

[75] S. N. Ooft, F. Weeber, K. K. Dijkstra, et al., “Patient-Derived Organoids Can Predict Response to Chemotherapy in Metastatic Colorectal Cancer Patients,” Science Translational Medicine 11, no. 513 (2019): eaay2574.

[76] V. Narasimhan, J. A. Wright, M. Churchill, et al., “Medium-Throughput Drug Screening of Patient-Drived Organoids From Colorectal Peritoneal Metastases to Direct Personalized Therapy,” Clinical Cancer Research 26, no. 14 (2020): 3662–3670.

[77] D. Schumacher, G. Andrieux, K. Boehnke, et al., “Heterogeneous Pathway Activation and Drug Response Modelled in Colorectal-Tumor-Derived 3D Cultures,” PLOS Genetics 15, no. 3 (2019): e1008076.

[78] E. Driehuis, A. van Hoeck, K. Moore, et al., “Pancreatic Cancer Organoids Recapitulate Disease and Allow Personalized Drug Screening,” PNAS 116, no. 52 (2019): 26580–26590.

[79] H. Tiriac, P. Belleau, D. D. Engle, et al., “Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer,” Cancer Discovery 8, no. 9 (2018): 1112–1129.

[80] J. T. Sharick, C. M. Walsh, C. M. Sprackling, et al., “Metabolic Heterogeneity in Patient Tumor-Derived Organoids by Primary Site and Drug Treatment,” Frontiers in Oncology 10 (2020): 553.

[81] S. Nuciforo, I. Fofana, M. S. Matter, et al., “Organoid Models of Human Liver Cancers Derived From Tumor Needle Biopsies,” Cell Reports 24, no. 5 (2018): 1363–1376.

[82] N. Sachs, J. de Ligt, O. Kopper, et al., “A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity,” Cell 172, no. 1–2 (2018): 373–386.e10.

[83] H. H. Yan, H. C. Siu, S. Law, et al., “A Comprehensive Human Gastric Cancer Organoid Biobank Captures Tumor Subtype Heterogeneity and Enables Therapeutic Screening,” Cell Stem Cell 23, no. 6 (2018): 882–897.e11.

[84] G. Vlachogiannis, S. Hedayat, A. Vatsiou, et al., “Patient-Derived Organoids Model Treatment Response of Metastatic Gastrointestinal Cancers,” Science 359, no. 6378 (2018): 920–926.

[85] Y. Yao, X. Xu, L. Yang, et al., “Patient-Derived Organoids Predict Chemoradiation Responses of Locally Advanced Rectal Cancer,” Cell Stem Cell 26, no. 1 (2020): 17–26.e6.

[86] M. L. Beshiri, C. M. Tice, C. Tran, et al., “A PDX/Organoid Biobank of Advanced Prostate Cancers Captures Genomic and Phenotypic Heterogeneity for Disease Modeling and Therapeutic Screening,” Clinical Cancer Research 24, no. 17 (2018): 4332–4345.

[87] J. Liu, P. Li, L. Wang, et al., “Cancer-Associated Fibroblasts Provide a Stromal Niche for Liver Cancer Organoids That Confers Trophic Effects and Therapy Resistance,” Cellular and Molecular Gastroenterology and Hepatology 11, no. 2 (2021): 407–431.

[88] E. Kim, S. Choi, B. Kang, et al., “Creation of Bladder Assembloids Mimicking Tissue Regeneration and Cancer,” Nature 588, no. 7839 (2020): 664–669.

[89] S. Tsai, L. McOlash, K. Palen, et al., “Development of Primary human Pancreatic Cancer Organoids, Matched Stromal and Immune Cells and 3D Tumor Microenvironment Models,” BMC Cancer 18, no. 1 (2018): 335.

[90] G. Scognamiglio, A. De Chiara, A. Parafioriti, et al., “Patient-Derived Organoids as a Potential Model to Predict Response to PD-1/PD-L1 Checkpoint Inhibitors,” British Journal of Cancer 121, no. 11 (2019): 979–982.

[91] K. I. Votanopoulos, S. Forsythe, H. Sivakumar, et al., “Model of Patient-Specific Immune-Enhanced Organoids for Immunotherapy Screening: Feasibility Study,” Annals of Surgical Oncology 27, no. 6 (2020): 1956–1967.

[92] P. Voabil, M. de Bruijn, L. M. Roelofsen, et al., “An Ex Vivo Tumor Fragment Platform to Dissect Response to PD-1 Blockade in Cancer,” Nature Medicine 27, no. 7 (2021): 1250–1261.

[93] M. Chalabi, L. F. Fanchi, K. K. Dijkstra, et al., “Neoadjuvant Immunotherapy Leads to Pathological Responses in MMR-Proficient and MMR-Deficient Early-Stage Colon Cancers,” Nature Medicine 26, no. 4 (2020): 566–576.

[94] J. C. H. Kong, G. R. Guerra, R. M. Millen, et al., “Tumor-Infiltrating Lymphocyte Function Predicts Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer,” JCO Precision Oncology 2 (2018): 1–15.

[95] Z. Zhou, K. Van der Jeught, Y. Li, et al., “A T Cell-Engaging Tumor Organoid Platform for Pancreatic Cancer Immunotherapy,” Advanced Science (Weinheim) 10, no. 23 (2023): e2300548.

[96] S. Klein, C. Mauch, K. Brinker, et al., “Tumor Infiltrating Lymphocyte Clusters Are Associated With Response to Immune Checkpoint Inhibition in BRAF V600(E/K) Mutated Malignant Melanomas,” Scientific Reports 11, no. 1 (2021): 1834.

[97] K. K. Dijkstra, C. M. Cattaneo, F. Weeber, et al., “Generation of Tumor-Reactive T Cells by Co-Culture of Peripheral Blood Lymphocytes and Tumor Organoids,” Cell 174, no. 6 (2018): 1586–1598.e12.

[98] C. M. Cattaneo, K. K. Dijkstra, L. F. Fanchi, et al., “Tumor Organoid-T-Cell Coculture Systems,” Nature Protocols 15, no. 1 (2020): 15–39.

[99] Q. Meng, S. Xie, G. K. Gray, et al., “Empirical Identification and Validation of Tumor-Targeting T Cell Receptors From Circulation Using Autologous Pancreatic Tumor Organoids,” Journal for ImmunoTherapy of Cancer 9, no. 11 (2021): e003213.

[100] C. Wan, M. P. Keany, H. Dong, et al., “Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer,” Cancer Research 81, no. 1 (2021): 158–173.

[101] H. Shan, M. Chen, S. Zhao, et al., “Acoustic Virtual 3D Scaffold for Direct-Interacting Tumor Organoid-Immune Cell Coculture Systems,” Science Advances 10, no. 47 (2024): eadr4831.

[102] G. Grandl and C. Wolfrum, “Hemostasis, Endothelial Stress, Inflammation, and the Metabolic syndrome,” in Seminars in Immunopathology (Springer, 2018).

[103] D. Farber, “Tissues, Not Blood, Are Where Immune Cells Function,” Nature 593, no. 7860 (2021): 506–509.

[104] T. Krausgruber, N. Fortelny, V. Fife-Gernedl, et al., “Structural Cells Are Key Regulators of Organ-Specific Immune Responses,” Nature 583, no. 7815 (2020): 296–302.

[105] J. Parkin and B. Cohen, “An Overview of the Immune System,” Lancet 357, no. 9270 (2001): 1777–1789.

[106] A. Iwasaki and R. Medzhitov, “Control of Adaptive Immunity by the Innate Immune System,” Nature Immunology 16, no. 4 (2015): 343–353.

[107] A. Iwasaki and R. Medzhitov, “Regulation of Adaptive Immunity by the Innate Immune System,” Science 327, no. 5963 (2010): 291–295.

[108] A. Luster, R. Alon, and U. Von Andrian, “Immune Cell Migration in Inflammation: Present and Future Therapeutic Targets,” Nature Immunology 6, no. 12 (2005): 1182–1190.

[109] G. Schett, D. Elewaut, I. B. McInnes, J. Dayer, and M. F. Neurath, “How Cytokine Networks Fuel Inflammation: Toward a Cytokine-Based Disease Taxonomy,” Nature Medicine 19, no. 7 (2013): 822–824.

[110] S. H. Park, K. Kang, E. Giannopoulou, et al., “Type I Interferons and the Cytokine TNF Cooperatively Reprogram the Macrophage Epigenome to Promote Inflammatory Activation,” Nature Immunology 18, no. 10 (2017): 1104–1116.

[111] N. Fujiwara and K. Kobayashi, “Macrophages in Inflammation,” Current Drug Targets-Inflammation & Allergy 4, no. 3 (2005): 281–286.

[112] P. A. Szabo, P. Dogra, J. I. Gray, et al., “Longitudinal Profiling of Respiratory and Systemic Immune Responses Reveals Myeloid Cell-Driven Lung Inflammation in Severe COVID-19,” Immunity 54, no. 4 (2021): 797–814.e6.

[113] M. Scharenberg, S. Vangeti, E. Kekäläinen, et al., “Influenza A Virus Infection Induces Hyperresponsiveness in Human Lung Tissue-Resident and Peripheral Blood NK Cells,” Frontiers in Immunology 10 (2019): 1116.

[114] M. A. Hernández-Castañeda, K. Happ, F. Cattalani, et al., “γδ T Cells Kill Plasmodium falciparum in a Granzyme-and Granulysin-Dependent Mechanism During the Late Blood Stage,” Journal of Immunology 204, no. 7 (2020): 1798–1809.

[115] M. Silva, “Neutrophils and Macrophages Work in Concert as Inducers and Effectors of Adaptive Immunity Against Extracellular and Intracellular Microbial Pathogens,” Journal of Leukocyte Biology 87, no. 5 (2010): 805–813.

[116] K. Good-Jacobson and J. Groom, “Tailoring Immune Responses Toward Autoimmunity: Transcriptional Regulators That Drive the Creation and Collusion of Autoreactive Lymphocytes,” Frontiers in Immunology 9 (2018): 482.

[117] J. S. Marshall, R. Warrington, W. Watson, and H. L. Kim, “An Introduction to Immunology and Immunopathology,” Allergy, Asthma & Clinical Immunology 14, suppl. no. 2 (2018): 49.

[118] C. D. Buckley, D. W. Gilroy, C. N. Serhan, B. Stockinger, and P. P. Tak, “The Resolution of Inflammation,” Nature Reviews Immunology 13, no. 1 (2013): 59–66.

[119] N. Wu, E. Sun, D. Liu, and D. Yu, “Tissue-Specific Immunity in Homeostasis and Diseases,” Journal of Immunology Research 2019 (2019): 7616509.

[120] S. Weisberg, B. Ural, and D. Farber, “Tissue-Specific Immunity for a Changing World,” Cell 184, no. 6 (2021): 1517–1529.

[121] E. Bentley and S. Little, “Local Delivery Strategies to Restore Immune Homeostasis in the Context of Inflammation,” Advanced Drug Delivery Reviews 178 (2021): 113971.

[122] W. Fan, K. M. Christian, H. Song, and G. Ming, “Applications of Brain Organoids for Infectious Diseases,” Journal of Molecular Biology 434, no. 3 (2022): 167243.

[123] E. Pellegrino and M. Gutierrez, “Human Stem Cell-Based Models for Studying Host-Pathogen Interactions,” Cellular Microbiology 23, no. 7 (2021): e13335.

[124] S. Zhao, X. Wu, Z. Tan, et al., “Generation of Human Embryonic Stem Cell-Derived Lung Organoids for Modeling Infection and Replication Differences Between Human Adenovirus Types 3 and 55 and Evaluating Potential Antiviral Drugs,” Journal of Virology 97, no. 5 (2023): e00209–23.

[125] A. P. Wong, C. E. Bear, S. Chin, et al., “Directed Differentiation of Human Pluripotent Stem Cells Into Mature Airway Epithelia Expressing Functional CFTR Protein,” Nature Biotechnology 30, no. 9 (2012): 876–882.

[126] S. Konishi, S. Gotoh, K. Tateishi, et al., “Directed Induction of Functional Multi-Ciliated Cells in Proximal Airway Epithelial Spheroids From Human Pluripotent Stem Cells,” Stem Cell Reports 6, no. 1 (2016): 18–25.

[127] I. Heo, D. Dutta, D. A. Schaefer, et al., “Modelling Cryptosporidium Infection in human Small Intestinal and Lung Organoids,” Nature Microbiology 3, no. 7 (2018): 814–823.

[128] S. Blutt and M. Estes, “Organoid Models for Infectious Disease,” Annual Review of Medicine 73, no. 1 (2022): 167–182.

[129] Y. Han, X. Duan, L. Yang, et al., “Identification of SARS-CoV-2 Inhibitors Using Lung and Colonic Organoids,” Nature 589, no. 7841 (2021): 270–275.

[130] J. Zhou, C. Li, N. Sachs, et al., “Differentiated human Airway Organoids to Assess Infectivity of Emerging Influenza Virus,” Proceedings of the National Academy of Sciences 115, no. 26 (2018): 6822–6827.

[131] S. Matsuyama, N. Nao, K. Shirato, et al., “Enhanced Isolation of SARS-CoV-2 by TMPRSS2-Expressing Cells,” Proceedings of the National Academy of Sciences 117, no. 13 (2020): 7001–7003.

[132] J. Zhou, C. Li, X. Liu, et al., “Infection of Bat and Human Intestinal Organoids by SARS-CoV-2,” Nature Medicine 26, no. 7 (2020): 1077–1083.

[133] A. Deenadayalan, P. Maddineni, and A. Raja, “Comparison of Whole Blood and PBMC Assays for T-Cell Functional Analysis,” BMC Research Notes 6 (2013): 1–5.

[134] D. Louz, H. E. Bergmans, B. P. Loos, and R. C. Hoeben, “Animal Models in Virus Research: Their Utility and Limitations,” Critical Reviews in Microbiology 39, no. 4 (2013): 325–361.

[135] W. Wang, P. Liu, W. Zhu, et al., “Skin Organoid Transplantation Promotes Tissue Repair With Scarless in Frostbite,” Protein & Cell 16, no. 4 (2025): 240–259.

[136] L. E. Wagar, A. Salahudeen, C. M. Constantz, et al., “Modeling Human Adaptive Immune Responses With Tonsil Organoids,” Nature Medicine 27, no. 1 (2021): 125–135.

[137] J. M. Kastenschmidt, S. Sureshchandra, A. Jain, et al., “Influenza Vaccine Format Mediates Distinct Cellular and Antibody Responses in Human Immune Organoids,” Immunity 56, no. 8 (2023): 1910–1926.e7.

[138] B. Laidlaw and A. Ellebedy, “The Germinal Centre B Cell Response to SARS-CoV-2,” Nature Reviews Immunology 22, no. 1 (2022): 7–18.

[139] H. Seo, H. Han, Y. Lee, Y. Noh, S. Cho, and J. Kim, “Human Pluripotent Stem Cell-Derived Alveolar Organoid With Macrophages,” International Journal of Molecular Sciences 23, no. 16 (2022): 9211.

[140] N. Bertaux-Skeirik, R. Feng, M. A. Schumacher, et al., “CD44 Plays a Functional Role in Helicobacter pylori-Induced Epithelial Cell Proliferation,” PLOS Pathogens 11, no. 2 (2015): e1004663.

[141] S. Idowu, P. Bertrand, and A. Walduck, “Gastric Organoids: Advancing the Study of H. pylori Pathogenesis and Inflammation,” Helicobacter 27, no. 3 (2022): e12891.

[142] M. Pompaiah and S. Bartfeld, “Gastric Organoids: An Emerging Model System to Study Helicobacter pylori Pathogenesis,” Molecular Pathogenesis and Signal Transduction By Helicobacter Pylori 400 (2017): 149–168.

[143] I. García-Rodríguez, A. Sridhar, D. Pajkrt, and K. C. Wolthers, “Put Some Guts Into It: Intestinal Organoid Models to Study Viral Infection,” Viruses 12, no. 11 (2020): 1288.

[144] Y. Li, N. Yang, J. Chen, et al., “Next-Generation Porcine Intestinal Organoids: An Apical-Out Organoid Model for Swine Enteric Virus Infection and Immune Response Investigations,” Journal of Virology 94, no. 21 (2020): e01006–20.

[145] J. Yan, C. Racaud-Sultan, T. Pezier, et al., “Intestinal Organoids to Model Salmonella Infection and Its Impact on Progenitors,” Scientific Reports 14, no. 1 (2024): 15160.

[146] S. S. Karve, S. Pradhan, D. V. Ward, and A. A. Weiss, “Intestinal Organoids Model Human Responses to Infection by Commensal and Shiga Toxin Producing Escherichia coli,” PLoS ONE 12, no. 6 (2017): e0178966.

[147] D. Zhang, M. Tan, W. Zhong, M. Xia, P. Huang, and X. Jiang, “Human Intestinal Organoids Express Histo-Blood Group Antigens, Bind Norovirus VLPs, and Support Limited Norovirus Replication,” Scientific Reports 7, no. 1 (2017): 12621.

[148] K. Ettayebi, G. Kaur, K. Patil, et al., “Insights Into Human Norovirus Cultivation in Human Intestinal Enteroids,” mSphere 9, no. 11 (2024): e00448–24.

[149] J. A. Depla, L. A. Mulder, R. V. de Sá, et al., “Human Brain Organoids as Models for Central Nervous System Viral Infection,” Viruses 14, no. 3 (2022): 634.

[150] J. Antonucci and L. Gehrke, “Cerebral Organoid Models for Neurotropic Viruses,” ACS Infectious Diseases 5, no. 12 (2019): 1976–1979.

[151] J. Steffen, Studies on the Pathogenesis of West Nile Virus Encephalitis in a Human Cerebral Organoid Model and Immortalized Cell Lines (Staats-und Universitätsbibliothek Hamburg Carl von Ossietzky, 2023).

[152] J. Dang, S. K. Tiwari, G. Lichinchi, et al., “Zika Virus Depletes Neural Progenitors in Human Cerebral Organoids Through Activation of the Innate Immune Receptor TLR3,” Cell Stem Cell 19, no. 2 (2016): 258–265.

[153] P. Ostermann and H. Schaal, “Human Brain Organoids to Explore SARS-CoV-2-Induced Effects on the Central Nervous System,” Reviews in Medical Virology 33, no. 2 (2023): e2430.

[154] Z. Zhao, X. Chen, A. M. Dowbaj, et al., “Organoids,” Nature Reviews Methods Primers 2, no. 1 (2022): 94.

[155] J. Yuan, X. Li, and S. Yu, “Cancer Organoid Co-Culture Model System: Novel Approach to Guide Precision Medicine,” Frontiers in Immunology 13 (2023): 1061388.

[156] D. Papp, T. Korcsmaros, and I. Hautefort, “Revolutionizing Immune Research With Organoid-Based Co-Culture and Chip Systems,” Clinical and Experimental Immunology 218, no. 1 (2024): 40–54.

[157] V. Bozzetti and S. Senger, “Organoid Technologies for the Study of Intestinal Microbiota–Host Interactions,” Trends in Molecular Medicine 28, no. 4 (2022): 290–303.

[158] Q. Xu, Y.-J. Wang, Y. He, et al., “Single-Cell RNA Sequencing of iPSC-Derived Brain Organoids Reveals <em>Treponema pallidum</em> Infection Inhibiting Neurodevelopment.” BioRxiv (2024): 20240123576898, https://doi.org/10.1101/2024.01.23.576898.

[159] A. Rybak-Wolf, E. Wyler, T. M. Pentimalli, et al., “Modelling Viral Encephalitis Caused by Herpes Simplex Virus 1 Infection in Cerebral Organoids,” Nature Microbiology 8, no. 7 (2023): 1252–1266.

[160] B. Meresse, Z. Chen, C. Ciszewski, et al., “Coordinated Induction by IL15 of a TCR-Independent NKG2D Signaling Pathway Converts CTL Into Lymphokine-Activated Killer Cells in Celiac Disease,” Immunity 21, no. 3 (2004): 357–366.

[161] A. J. M. Santos, V. van Unen, Z. Lin, et al., “A Human Autoimmune Organoid Model Reveals IL-7 Function in Coeliac Disease,” Nature 632, no. 8024 (2024): 401–410.

[162] D. Furman, J. Campisi, E. Verdin, et al., “Chronic Inflammation in the Etiology of Disease Across the Life Span,” Nature Medicine 25, no. 12 (2019): 1822–1832.

[163] M. Neurath, “Cytokines in Inflammatory Bowel Disease,” Nature Reviews Immunology 14, no. 5 (2014): 329–342.

[164] L. M. Spekhorst, M. C. Visschedijk, R. K. Weersma, and E. A. Festen, “Down the Line From Genome-Wide Association Studies in Inflammatory Bowel Disease: The Resulting Clinical Benefits and the Outlook for the Future,” Expert Review of Clinical Immunology 11, no. 1 (2015): 33–44.

[165] M. Neurath, “Targeting Immune Cell Circuits and Trafficking in Inflammatory Bowel Disease,” Nature Immunology 20, no. 8 (2019): 970–979.

[166] K. Yeshi, R. Ruscher, L. Hunter, N. L. Daly, A. Loukas, and P. Wangchuk, “Revisiting Inflammatory Bowel Disease: Pathology, Treatments, Challenges and Emerging Therapeutics Including Drug Leads From Natural Products,” Journal of Clinical Medicine 9, no. 5 (2020): 1273.

[167] H. Liu, J. Sun, M. Wang, S. Wang, J. Su, and C. Xu, “Intestinal Organoids and Organoids Extracellular Vesicles for Inflammatory Bowel Disease Treatment,” Chemical Engineering Journal 465 (2023): 142842.

[168] S. Sakib and S. Zou, “Attenuation of Chronic Inflammation in Intestinal Organoids With Graphene Oxide-Mediated Tumor Necrosis Factor-α_Small Interfering RNA Delivery,” Langmuir 40, no. 7 (2024): 3402–3413.

[169] B. Ojo, K. VanDussen, and M. Rosen, “The Promise of Patient-Derived Colon Organoids to Model Ulcerative Colitis,” Inflammatory Bowel Diseases 28, no. 2 (2022): 299–308.

[170] S. Watanabe, S. Kobayashi, N. Ogasawara, et al., “Transplantation of Intestinal Organoids Into a Mouse Model of Colitis,” Nature Protocols 17, no. 3 (2022): 649–671.

[171] E. d'Aldebert, M. Quaranta, M. Sébert, et al., “Characterization of Human Colon Organoids From Inflammatory Bowel Disease Patients,” Frontiers in Cell and Developmental Biology 8 (2020): 542034.

[172] L. O'Connell, D. Winter, and C. Aherne, “The Role of Organoids as a Novel Platform for Modeling of Inflammatory Bowel Disease,” Frontiers in Pediatrics 9 (2021): 624045.

[173] J. Bebb and B. Scott, “How Effective Are the Usual Treatments for Ulcerative Colitis?,” Alimentary Pharmacology & Therapeutics 20, no. 2 (2004): 143–149.

[174] D. Low, D. Nguyen, and E. Mizoguchi, “Animal Models of Ulcerative Colitis and Their Application in Drug Research,” Drug Design, Development and Therapy 7 (2013): 1341–1357.

[175] S. Milev, M. D. DiBonaventura, P. Quon, et al., “An Economic Evaluation of Tofacitinib for the Treatment of Moderately-to-Severely Active Ulcerative Colitis: Modeling the Cost of Treatment Strategies in the United States,” Journal of Medical Economics 22, no. 9 (2019): 859–868.

[176] S. K. Sarvestani, S. Signs, B. Hu, et al., “Induced Organoids Derived From Patients With Ulcerative Colitis Recapitulate Colitic Reactivity,” Nature Communications 12, no. 1 (2021): 262.

[177] A. Hazrati, K. Malekpour, S. Soudi, and S. M. Hashemi, “Mesenchymal Stromal/Stem Cells and Their Extracellular Vesicles Application in Acute and Chronic Inflammatory Liver Diseases: Emphasizing on the Anti-Fibrotic and Immunomodulatory Mechanisms,” Frontiers in Immunology 13 (2022): 865888.

[178] I. Laudadio, C. Carissimi, N. Scafa, et al., “Characterization of Patient-Derived Intestinal Organoids for Modelling Fibrosis in Inflammatory Bowel Disease,” Inflammation Research 73, no. 8 (2024): 1359–1370.

[179] J. Gray and D. Farber, “Tissue-Resident Immune Cells in Humans,” Annual Review of Immunology 40, no. 1 (2022): 195–220.

[180] E. Kolaczkowska and P. Kubes, “Neutrophil Recruitment and Function in Health and Inflammation,” Nature Reviews Immunology 13, no. 3 (2013): 159–175.

[181] S. E. Hall, J. S. Savill, P. M. Henson, and C. Haslett, “Apoptotic Neutrophils Are Phagocytosed by Fibroblasts With Participation of the Fibroblast Vitronectin Receptor and Involvement of a Mannose/Fucose-Specific Lectin,” Journal of Immunology (Baltimore, Md: 1950) 153, no. 7 (1994): 3218–3227.

[182] G. Leoni, P. Neumann, R. Sumagin, T. L. Denning, and A. Nusrat, “Wound Repair: Role of Immune-Epithelial Interactions,” Mucosal Immunology 8, no. 5 (2015): 959–968.

[183] T. Wynn and K. Vannella, “Macrophages in Tissue Repair, Regeneration, and Fibrosis,” Immunity 44, no. 3 (2016): 450–462.

[184] S. Kim and M. Nair, “Macrophages in Wound Healing: Activation and Plasticity,” Immunology and Cell Biology 97, no. 3 (2019): 258–267.

[185] J. Diao, J. Liu, S. Wang, et al., “Sweat Gland Organoids Contribute to Cutaneous Wound Healing and Sweat Gland Regeneration,” Cell Death & Disease 10, no. 3 (2019): 238.

[186] R. Cruz-Acuña, M. Quirós, A. E. Farkas, et al., “Synthetic Hydrogels for Human Intestinal Organoid Generation and Colonic Wound Repair,” Nature Cell Biology 19, no. 11 (2017): 1326–1335.

[187] F. Zhang, Z. Hu, Y. Wang, et al., “Organoids Transplantation Attenuates Intestinal Ischemia/Reperfusion Injury in Mice Through L-Malic Acid-Mediated M2 Macrophage Polarization,” Nature Communications 14, no. 1 (2023): 6779.

[188] T. Zhang, S. Sheng, W. Cai, et al., “3-D Bioprinted Human-Derived Skin Organoids Accelerate Full-Thickness Skin Defects Repair,” Bioactive Materials 42 (2024): 257–269.

[189] C. Lee, S. Hong, E. Kim, D. Chang, and Y. Kim, “Epithelial Regeneration Ability of Crohn's Disease Assessed Using Patient-Derived Intestinal Organoids,” International Journal of Molecular Sciences 22, no. 11 (2021): 6013.

[190] J. Qian, E. Lu, H. Xiang, et al., “GelMA Loaded With Exosomes From human minor Salivary Gland Organoids Enhances Wound Healing by Inducing Macrophage Polarization,” Journal of Nanobiotechnology 22, no. 1 (2024): 550.

[191] G. J. Randolph, S. Ivanov, B. H. Zinselmeyer, and J. P. Scallan, “The Lymphatic System: Integral Roles in Immunity,” Annual Review of Immunology 35, no. 1 (2017): 31–52.

[192] A. de Janon, A. Mantalaris, and N. Panoskaltsis, “Three-Dimensional Human Bone Marrow Organoids for the Study and Application of Normal and Abnormal Hematoimmunopoiesis,” Journal of Immunology 210, no. 7 (2023): 895–904.

[193] A. O. Khan, A. Rodriguez-Romera, J. S. Reyat, et al., “Human Bone Marrow Organoids for Disease Modeling, Discovery, and Validation of Therapeutic Targets in Hematologic Malignancies,” Cancer Discovery 13, no. 2 (2023): 364–385.

[194] A. Olijnik, A. Rodriguez-Romera, Z. C. Wong, et al., “Generating Human Bone Marrow Organoids for Disease Modeling and Drug Discovery,” Nature Protocols 19, no. 7 (2024): 2117–2146.

[195] S. Frenz-Wiessner, S. D. Fairley, M. Buser, et al., “Generation of Complex Bone Marrow Organoids From Human Induced Pluripotent Stem Cells,” Nature Methods 21, no. 5 (2024): 868–881.

[196] F. A. Flomerfelt, N. El Kassar, C. Gurunathan, et al., “Tbata Modulates Thymic Stromal Cell Proliferation and thymus Function,” Journal of Experimental Medicine 207, no. 11 (2010): 2521–2532.

[197] Y. Fan, A. Tajima, S. K. Goh, et al., “Bioengineering Thymus Organoids to Restore Thymic Function and Induce Donor-Specific Immune Tolerance to Allografts,” Molecular Therapy 23, no. 7 (2015): 1262–1277.

[198] C. S. Seet, C. He, M. T. Bethune, et al., “Generation of Mature T Cells From Human Hematopoietic Stem and Progenitor Cells in Artificial Thymic Organoids,” Nature Methods 14, no. 5 (2017): 521–530.

[199] M. Poznansky, R. H. Evans, R. B. Foxall, et al., “Efficient Generation of Human T Cells From a Tissue-Engineered Thymic Organoid,” Nature Biotechnology 18, no. 7 (2000): 729–734.

[200] G. Awong, E. Herer, R. N. La Motte-Mohs, and J. C. Zúñiga-Pflücker, “Human CD8 T Cells Generated In Vitro From Hematopoietic Stem Cells Are Functionally Mature,” BMC Immunology 12 (2011): 1–9.

[201] S. A. Ramos, L. H. Armitage, J. J. Morton, et al., “Generation of Functional Thymic Organoids From Human Pluripotent Stem Cells,” Stem Cell Reports 18, no. 4 (2023): 829–840.

[202] T. Hübscher, L. F. Lorenzo-Martín, T. Barthlott, et al., “Thymic Epithelial Organoids Mediate T-Cell Development,” Development (Cambridge, England) 151, no. 17 (2024): dev202853.

[203] C. D. C. Allen, T. Okada, H. L. Tang, and J. G. Cyster, “Imaging of Germinal Center Selection Events During Affinity Maturation,” Science 315, no. 5811 (2007): 528–531.

[204] E. Lenti, S. Bianchessi, S. T. Proulx, et al., “Therapeutic Regeneration of Lymphatic and Immune Cell Functions Upon Lympho-Organoid Transplantation,” Stem Cell Reports 12, no. 6 (2019): 1260–1268.

[205] G. Goyal, P. Prabhala, G. Mahajan, et al., “Lymphoid Follicle Formation and human Vaccination Responses Recapitulated in an Organ-on-a-chip,” BioRxiv (2021): 806505, https://doi.org/10.1101/806505.

[206] S. Lewis, A. Williams, and S. Eisenbarth, “Structure and Function of the Immune System in the Spleen,” Science Immunology 4, no. 33 (2019): eaau6085.

[207] D. Irvine, A. Stachowiak, and Y. Hori, “Lymphoid Tissue Engineering: Invoking Lymphoid Tissue Neogenesis in Immunotherapy and Models of immunity,” in Seminars in Immunology (Elsevier, 2008).

[208] A. Purwada, M. K. Jaiswal, H. Ahn, et al., “Ex Vivo Engineered Immune Organoids for Controlled Germinal Center Reactions,” Biomaterials 63 (2015): 24–34.

[209] A. Purwada and A. Singh, “Immuno-Engineered Organoids for Regulating the Kinetics of B-Cell Development and Antibody Production,” Nature Protocols 12, no. 1 (2017): 168–182.

[210] K. Gee, M. A. Isani, A. Fode, et al., “Spleen Organoid Units Generate Functional Human and Mouse Tissue-Engineered Spleen in a Murine Model,” Tissue Engineering Part A 26, no. 7–8 (2020): 411–418.

[211] A. Olijnik, A. Rodriguez-Romera, Z. C. Wong, et al., “Generating Human Bone Marrow Organoids for Disease Modeling and Drug Discovery,” Nature Protocols 19, no. 7 (2024): 2117–2146.

[212] S. Frenz-Wiessner, S. D. Fairley, M. Buser, et al., “Generation of Complex Bone Marrow Organoids From Human Induced Pluripotent Stem Cells,” Nature Methods 21, no. 5 (2024): 868–881.

[213] T. Hübscher, L. F. Lorenzo-Martín, T. Barthlott, et al., “Thymic Epithelial Organoids Mediate T-Cell Development,” Development (Cambridge, England) 151, no. 17 (2024): dev202853.

[214] E. Gerasimova, A. C. Beenen, D. Kachkin, et al., “Novel Co-Culture Model of T Cells and Midbrain Organoids for Investigating Neurodegeneration in Parkinson's Disease,” NPJ Parkinson's Disease 11, no. 1 (2025): 36.

[215] A. I. Vazquez-Armendariz, M. Heiner, E. El Agha, et al., “Multilineage Murine Stem Cells Generate Complex Organoids to Model Distal Lung Development and Disease,” EMBO Journal 39, no. 21 (2020): e103476.

[216] A. Usui-Ouchi, S. Giles, S. Harkins-Perry, et al., “Integrating Human iPSC-Derived Macrophage Progenitors Into Retinal Organoids to Generate a Mature Retinal Microglial Niche,” Glia 71, no. 10 (2023): 2372–2382.

[217] A Tissue-engineered Artificial human thymus From human iPSCs to Study T Cell Immunity. Nature Methods 19, no. 10 (2022): 1191–1192.

[218] N. A. Pirjanian, K. Kalpana, I. Kruglikov, et al., “Establishing Neural Organoid Cultures for Investigating the Effects of Microgravity in Low-Earth Orbit (LEO),” in Methods in Molecular Biology (Springer, 2024), https://doi.org/10.1007/7651_2024_550.

[219] C. S. Seet, C. He, M. T. Bethune, et al., “Generation of Mature T Cells From Human Hematopoietic Stem and Progenitor Cells in Artificial Thymic Organoids,” Nature Methods 14, no. 5 (2017): 521–530.

[220] T. Recaldin, L. Steinacher, B. Gjeta, et al., “Human Organoids With an Autologous Tissue-Resident Immune Compartment,” Nature 633, no. 8028 (2024): 165–173.

[221] R. R. Schreurs, M. E. Baumdick, A. Drewniak, and M. J. Bunders, “In Vitro Co-Culture of Human Intestinal Organoids and Lamina Propria-Derived CD4+ T Cells,” STAR Protocols 2, no. 2 (2021): 100519.

[222] G. M. Jowett, E. Read, L. B. Roberts, et al., “Organoids Capture Tissue-Specific Innate Lymphoid Cell Development in Mice and Humans,” Cell Reports 40, no. 9 (2022): 111281.

[223] E. Bonaiti, M. G. Muraro, P. A. Robert, et al., “Tonsil Explants as a Human In Vitro Model to Study Vaccine Responses,” Frontiers in Immunology 15 (2024): 1425455.

[224] Z. W. Wagoner, T. B. Yates, J. E. Hernandez-Davies, et al., “Systems Immunology Analysis of Human Immune Organoids Identifies Host-Specific Correlates of Protection to Different Influenza Vaccines,” Cell Stem Cell 32, no. 4 (2025): 529–546.e6.

[225] M. Mostina, J. Sun, S. L. Sim, et al., “Coordinated Development of Immune Cell Populations in Vascularized Skin Organoids From Human Induced Pluripotent Stem Cells,” Advanced Healthcare Materials (2025): e02108, https://doi.org/10.1002/adhm.202502108.

[226] A. Autengruber, M. Gereke, G. Hansen, C. Hennig, and D. Bruder, “Impact of Enzymatic Tissue Disintegration on the Level of Surface Molecule Expression and Immune Cell Function,” European Journal of Microbiology and Immunology (Bp) 2, no. 2 (2012): 112–120.

[227] E. Wang, K. Xiang, Y. Zhang, et al., “Patient-Derived Organoids (PDOs) and PDO-Derived Xenografts (PDOXs): New Opportunities in Establishing Faithful Pre-Clinical Cancer Models,” Journal of the National Cancer Center 2, no. 4 (2022): 263–276.

[228] G. Zhou, R. Lieshout, G. S. van Tienderen, et al., “Modelling Immune Cytotoxicity for Cholangiocarcinoma With Tumour-Derived Organoids and Effector T Cells,” British Journal of Cancer 127, no. 4 (2022): 649–660.

[229] R. Gentek, K. Molawi, and M. Sieweke, “Tissue Macrophage Identity and Self-Renewal,” Immunological Reviews 262, no. 1 (2014): 56–73.

[230] K. Saha and R. Jaenisch, “Technical Challenges in Using Human Induced Pluripotent Stem Cells to Model Disease,” Cell Stem Cell 5, no. 6 (2009): 584–595.

[231] I. Jurickova, B. W. Dreskin, E. Angerman, et al., “Eicosatetraynoic Acid Regulates Pro-Fibrotic Pathways in an Induced Pluripotent Stem Cell Derived Macrophage: Human Intestinal Organoid Model of Crohn's Disease,” BioRxiv (2024), https://doi.org/10.1101/2024.01.30.577959.

[232] J. O. Múnera, D. O. Kechele, C. Bouffi, et al., “Development of Functional Resident Macrophages in Human Pluripotent Stem Cell-Derived Colonic Organoids and Human Fetal Colon,” Cell Stem Cell 30, no. 11 (2023): 1434–1451.e9.

[233] M. Kondo, “Lymphoid and Myeloid Lineage Commitment in Multipotent Hematopoietic Progenitors,” Immunological Reviews 238, no. 1 (2010): 37–46.

[234] E. Dzierzak and N. Speck, “Of Lineage and Legacy: The Development of Mammalian Hematopoietic Stem Cells,” Nature Immunology 9, no. 2 (2008): 129–136.

[235] M. Raulf-Heimsoth, “T Cell—Primary Culture From Peripheral Blood,” in Allergy Methods and Protocols (Humana Press, 2008), 17–30.

[236] S. Raab, M. Klingenstein, S. Liebau, and L. Linta, “A Comparative View on Human Somatic Cell Sources for iPSC Generation,” Stem Cells International 2014 (2014): 768391.

[237] J. Wang, C. Chen, L. Wang, et al., “Patient-Derived Tumor Organoids: New Progress and Opportunities to Facilitate Precision Cancer Immunotherapy,” Frontiers in Oncology 12 (2022): 872531.

[238] V. Azimian Zavareh, L. Rafiee, M. Sheikholeslam, et al., “Three-Dimensional In Vitro Models: A Promising Tool To Scale-Up Breast Cancer Research,” ACS Biomaterials Science & Engineering 8, no. 11 (2022): 4648–4672.

[239] J. Chakrabarti, L. Holokai, L. Syu, et al., “Hedgehog Signaling Induces PD-L1 Expression and Tumor Cell Proliferation in Gastric Cancer,” Oncotarget 9, no. 100 (2018): 37439–37457.

[240] V. Velasco, S. Shariati, and R. Esfandyarpour, “Microtechnology-Based Methods for Organoid Models,” Microsystems & Nanoengineering 6 (2020): 76.

[241] S. Kaur, I. Kaur, P. Rawal, D. M. Tripathi, and A. Vasudevan, “Non-Matrigel Scaffolds for Organoid Cultures,” Cancer Letters 504 (2021): 58–66.

[242] L. Holokai, J. Chakrabarti, J. Lundy, et al., “Murine- and Human-Derived Autologous Organoid/Immune Cell Co-Cultures as Pre-Clinical Models of Pancreatic Ductal Adenocarcinoma,” Cancers (Basel) 12, no. 12 (2020): 3816.

[243] M. Andrews and A. Kriegstein, “Challenges of Organoid Research,” Annual Review of Neuroscience 45 (2022): 23–39.

[244] A. Marchini and F. Gelain, “Synthetic Scaffolds for 3D Cell Cultures and Organoids: Applications in Regenerative Medicine,” Critical Reviews in Biotechnology 42, no. 3 (2022): 468–486.

[245] Z. Zhao, X. Chen, A. M. Dowbaj, et al., “Organoids,” Nature Reviews Methods Primers 2 (2022): 94.

[246] Y. Shao, J. Wang, A. Jin, S. Jiang, L. Lei, and L. Liu, “Biomaterial-Assisted Organoid Technology for Disease Modeling and Drug Screening,” Materials Today Bio 30 (2025): 101438.

[247] K. Yu, W. Yuan, H. Wang, and Y. Li, “Extracellular Matrix Stiffness and Tumor-Associated Macrophage Polarization: New Fields Affecting Immune Exclusion,” Cancer Immunology, Immunotherapy 73, no. 6 (2024), 115, https://doi.org/10.1007/s00262-024-03675-9.

[248] A. Bogoslowski, M. An, and J. Penninger, “Incorporating Immune Cells Into Organoid Models: Essential for Studying Human Disease,” Organoids 2 (2023): 140–155.

[249] C. Aguilar, M. Alves da Silva, M. Saraiva, M. Neyazi, I. A. S. Olsson, and S. Bartfeld, “Organoids as Host Models for Infection Biology—A Review of Methods,” Experimental & Molecular Medicine 53, no. 10 (2021): 1471–1482.

[250] S. A. Aksoy, J. Earl, J. Grahovac, et al., “Organoids, Tissue Slices and Organotypic Cultures: Advancing Our Understanding of Pancreatic Ductal Adenocarcinoma Through In Vitro and Ex Vivo Models,” Seminars in Cancer Biology 109 (2025): 10–24.

[251] R. Polak, E. Zhang, and C. Kuo, “Cancer Organoids 2.0: Modelling the Complexity of the Tumour Immune Microenvironment,” Nature Reviews Cancer 24, no. 8 (2024): 523–539.

[252] A. Pagliaro, B. Artegiani, and D. Hendriks, “Emerging Approaches to Enhance Human Brain Organoid Physiology,” Trends in Cell Biology 35, no. 6 (2025): 483–499.

[253] E. Sendino Garví, G. J. J. van Slobbe, E. A. Zaal, et al., “KCNJ16-Depleted Kidney Organoids Recapitulate Tubulopathy and Lipid Recovery Upon Statins Treatment,” Stem Cell Research & Therapy 15, no. 1 (2024): 268.

[254] G. Stroulios, T. Brown, G. Moreni, et al., “Apical-Out Airway Organoids as a Platform for Studying Viral Infections and Screening for Antiviral Drugs,” Scientific Reports 12, no. 1 (2022): 7673.

[255] J. Sun, I. Ahmed, J. Brown, K. Khosrotehrani, and A. Shafiee, “The Empowering Influence of Air-Liquid Interface Culture on Skin Organoid Hair Follicle Development,” Burns Trauma 13 (2025): tkae070.

[256] S. Velasco, A. J. Kedaigle, S. K. Simmons, et al., “Individual Brain Organoids Reproducibly Form Cell Diversity of the Human Cerebral Cortex,” Nature 570, no. 7762 (2019): 523–527.

[257] J. R. Spence, C. N. Mayhew, S. A. Rankin, et al., “Directed Differentiation of Human Pluripotent Stem Cells Into Intestinal Tissue In Vitro,” Nature 470, no. 7332 (2011): 105–109.

[258] M. Fujii, M. Matano, K. Toshimitsu, et al., “Human Intestinal Organoids Maintain Self-renewal Capacity and Cellular Diversity in Niche-Inspired Culture Condition,” Cell Stem Cell 23, no. 6 (2018): 787–793.e6.

[259] Y. Bar-Ephraim, K. Kretzschmar, and H. Clevers, “Organoids in Immunological Research,” Nature Reviews Immunology 20, no. 5 (2020): 279–293.

[260] J. Kim, B. Koo, and K. Yoon, “Modeling Host-Virus Interactions in Viral Infectious Diseases Using Stem-Cell-Derived Systems and CRISPR/Cas9 Technology,” Viruses 11, no. 2 (2019): 124.

[261] M. Hofer and M. Lutolf, “Engineering Organoids,” Nature Reviews Materials 6, no. 5 (2021): 402–420.

[262] D. Lu and G. Kassab, “Role of Shear Stress and Stretch in Vascular Mechanobiology,” Journal of the Royal Society Interface 8, no. 63 (2011): 1379–1385.

[263] G. Abraham, C. Zizzadoro, J. Kacza, et al., “Growth and Differentiation of Primary and Passaged Equine Bronchial Epithelial Cells Under Conventional and Air-Liquid-Interface Culture Conditions,” BMC Veterinary Research 7 (2011): 1–13.

[264] A. Fatehullah, S. Tan, and N. Barker, “Organoids as an In Vitro Model of human Development and Disease,” Nature Cell Biology 18, no. 3 (2016): 246–254.

[265] D. de Jongh, E. K. Massey, E. Berishvili, et al., “Organoids: A Systematic Review of Ethical Issues,” Stem Cell Research & Therapy 13, no. 1 (2022): 337.

[266] V. Mollaki, “Ethical Challenges in Organoid Use,” Biotechniques 10, no. 3 (2021): 12.

[267] Y. S. Zhang, J. Aleman, S. R. Shin, et al., “Multisensor-Integrated Organs-on-Chips Platform for Automated and Continual In Situ Monitoring of Organoid Behaviors,” Proceedings of the National Academy of Sciences 114, no. 12 (2017): E2293–E2302.

[268] H. Liu, Z. Gan, X. Qin, Y. Wang, and J. Qin, “Advances in Microfluidic Technologies in Organoid Research,” Advanced Healthcare Materials 13, no. 21 (2024): 2302686.

[269] X. Wu, M. A. Newbold, Z. Gao, and C. L. Haynes, “A Versatile Microfluidic Platform for the Study of Cellular Interactions Between Endothelial Cells and Neutrophils,” Biochimica et Biophysica Acta (BBA) - General Subjects 1861, no. 5 pt. A (2017): 1122–1130.

[270] F. Yu, W. Hunziker, and D. Choudhury, “Engineering Microfluidic Organoid-on-a-Chip Platforms,” Micromachines (Basel) 10, no. 3 (2019): 165.

[271] M. V. Monteiro, Y. S. Zhang, V. M. Gaspar, and J. F. Mano, “3D-Bioprinted Cancer-on-a-Chip: Level-Up Organotypic In Vitro Models,” Trends in Biotechnology 40, no. 4 (2022): 432–447.

[272] M. A. Heinrich, R. Bansal, T. Lammers, Y. S. Zhang, R. Michel Schiffelers, and J. Prakash, “3D-Bioprinted Mini-Brain: A Glioblastoma Model to Study Cellular Interactions and Therapeutics,” Advanced Materials 31, no. 14 (2019): e1806590.

[273] S. Park, A. Georgescu, and D. Huh, “Organoids-on-a-Chip,” Science 364, no. 6444 (2019): 960–965.

[274] H. Fan, U. Demirci, and P. Chen, “Emerging Organoid Models: Leaping Forward in Cancer Research,” Journal of Hematology & Oncology 12, no. 1 (2019): 142.

[275] M. Hosseini, K. Koehler, and A. Shafiee, “Biofabrication of Human Skin With Its Appendages,” Advanced Healthcare Materials 11, no. 22 (2022): e2201626.

[276] J. Zhu, L. Ji, Y. Chen, et al., “Organoids and Organs-on-Chips: Insights Into Predicting the Efficacy of Systemic Treatment in Colorectal Cancer,” Cell Death Discovery 9, no. 1 (2023): 72.

[277] H. Jin, Z. Xue, J. Liu, B. Ma, J. Yang, and L. Lei, “Advancing Organoid Engineering for Tissue Regeneration and Biofunctional Reconstruction,” Biomaterials Research 28 (2024): 0016.

[278] X. Xie, X. Li, and W. Song, “Tumor Organoid Biobank – New Platform for Medical Research,” Scientific Reports 13, no. 1 (2023): 1819.

[279] D. Papp, T. Korcsmaros, and I. Hautefort, “Revolutionizing Immune Research With Organoid-Based Co-Culture and Chip Systems,” Clinical and Experimental Immunology 218, no. 1 (2024): 40–54.

[280] L. Magré, M. M. A. Verstegen, S. Buschow, L. J. W. van der Laan, M. Peppelenbosch, and J. Desai, “Emerging Organoid-Immune Co-Culture Models for Cancer Research: From Oncoimmunology to Personalized Immunotherapies,” Journal for ImmunoTherapy of Cancer 11, no. 5 (2023): e006290.

[281] H. Han, T. Zhan, N. Guo, M. Cui, and Y. Xu, “Cryopreservation of Organoids: Strategies, Innovation, and Future Prospects,” Biotechnology Journal 19, no. 2 (2024): 2300543.

[282] F. Perrone and M. Zilbauer, “Biobanking of Human Gut Organoids for Translational Research,” Experimental & Molecular Medicine 53, no. 10 (2021): 1451–1458.

[283] T. Kassis, V. Hernandez-Gordillo, R. Langer, and L. G. Griffith, “OrgaQuant: Human Intestinal Organoid Localization and Quantification Using Deep Convolutional Neural Networks,” Scientific Reports 9, no. 1 (2019): 12479.

[284] R. N. U. Kok, L. Hebert, G. Huelsz-Prince, et al., “OrganoidTracker: Efficient Cell Tracking Using Machine Learning and Manual Error Correction,” PLoS ONE 15, no. 10 (2020): e0240802.

[285] S. McAleer, A. Fast, Y. Xue, et al., “Deep Learning-Assisted Multiphoton Microscopy to Reduce Light Exposure and Expedite Imaging in Tissues With High and Low Light Sensitivity,” Translational Vision Science & Technology 10, no. 12 (2021): 30.

[286] A. S. Monzel, K. Hemmer, T. Kaoma, et al., “Machine Learning-Assisted Neurotoxicity Prediction in Human Midbrain Organoids,” Parkinsonism & Related Disorders 75 (2020): 105–109.

[287] K. Park, J. Y. Lee, S. Y. Lee, et al., “Deep Learning Predicts the Differentiation of Kidney Organoids Derived From Human Induced Pluripotent Stem Cells,” Kidney Research and Clinical Practice 42, no. 1 (2023): 75–85.

[288] Z. Zhang, Z. Xu, F. Yuan, K. Jin, and M. Xiang, “Retinal Organoid Technology: Where Are We Now?,” International Journal of Molecular Sciences 22, no. 19 (2021): 10244.

[289] E. Kegeles, A. Naumov, E. A. Karpulevich, P. Volchkov, and P. Baranov, “Convolutional Neural Networks Can Predict Retinal Differentiation in Retinal Organoids,” Frontiers in Cellular Neuroscience 14 (2020): 171.

[290] R. Serrano, D. A. Feyen, A. A. Bruyneel, et al., “A Deep Learning Platform to Assess Drug Proarrhythmia Risk,” Cell Stem Cell 30, no. 1 (2023): 86–95.e4.

[291] M. Juhola, K. Penttinen, H. Joutsijoki, and K. Aalto-Setälä, “Analysis of Drug Effects on iPSC Cardiomyocytes With Machine Learning,” Annals of Biomedical Engineering 49, no. 1 (2021): 129–138.

[292] D. Dutta, I. Heo, and H. Clevers, “Disease Modeling in Stem Cell-Derived 3D Organoid Systems,” Trends in Molecular Medicine 23, no. 5 (2017): 393–410.

[293] L. Bai, Y. Wu, G. Li, W. Zhang, H. Zhang, and J. Su, “AI-Enabled Organoids: Construction, Analysis, and Application,” Bioactive Materials 31 (2024): 525–548.

[294] T. Park, T. K. Kim, Y. D. Han, K. Kim, H. Kim, and H. S. Kim, “Development of a Deep Learning Based Image Processing Tool for Enhanced Organoid Analysis,” Scientific Reports 13, no. 1 (2023): 19841.

[295] Y. Fujimura, I. Sakai, I. Shioka, et al., “Machine Learning-Based Estimation of Spatial Gene Expression Pattern During ESC-Derived Retinal Organoid Development,” Scientific Reports 13, no. 1 (2023): 22781.

[296] Q. Yang, M. Li, Z. Xiao, Y. Feng, L. Lei, and S. Li, “A New Perspective on Precision Medicine: The Power of Digital Organoids,” Biomaterials Research 29 (2025): 0171.

[297] Y. Shen and Z. Kokaia, “Brain Organoid Transplantation: A Comprehensive Guide to the Latest Advances and Practical Applications – A Systematic Review,” Cells 14, no. 14 (2025): 1074.

[298] M. J. ten Dam, G. W. Frederix, R. M. ten Ham, L. J. van der Laan, and K. Schneeberger, “Toward Transplantation of Liver Organoids: From Biology and Ethics to Cost-Effective Therapy,” Transplantation 107, no. 8 (2023): 1706–1717.

[299] S. Watanabe, S. Kobayashi, N. Ogasawara, et al., “Transplantation of Intestinal Organoids Into a Mouse Model of Colitis,” Nature Protocols 17, no. 3 (2022): 649–671.

[300] A. S. Shankar, H. Tejeda-Mora, Z. Du, et al., “Interactions of the Immune System With Human Kidney Organoids,” Transplant International 37 (2024): 12468.

[301] M. Madrid, C. Sumen, S. Aivio, and N. Saklayen, “Autologous Induced Pluripotent Stem Cell-Based Cell Therapies: Promise, Progress, and Challenges,” Current Protocols 1, no. 3 (2021): e88.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.